0001562180-20-005393.txt : 20200811
0001562180-20-005393.hdr.sgml : 20200811
20200811165223
ACCESSION NUMBER: 0001562180-20-005393
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200807
FILED AS OF DATE: 20200811
DATE AS OF CHANGE: 20200811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DEKKERS MARIJN E
CENTRAL INDEX KEY: 0001216068
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38319
FILM NUMBER: 201093100
MAIL ADDRESS:
STREET 1: GENERAL ELECTRIC COMPANY
STREET 2: 41 FARNSWORTH STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Quanterix Corp
CENTRAL INDEX KEY: 0001503274
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 208957988
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 MIDDLESEX TURNPIKE
CITY: BILLERICA
STATE: MA
ZIP: 01821
BUSINESS PHONE: 617-301-9400
MAIL ADDRESS:
STREET 1: 900 MIDDLESEX TURNPIKE
CITY: BILLERICA
STATE: MA
ZIP: 01821
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-08-07
false
0001503274
Quanterix Corp
QTRX
0001216068
DEKKERS MARIJN E
C/O QUANTERIX CORPORATION,
900 MIDDLESEX TURNPIKE
BILLERICA
MA
01821
true
false
false
false
Common Stock
2020-08-07
4
S
false
27619.00
32.49
D
0.00
I
Held by Novalis LifeSciences Investments I, L.P.
Common Stock
6810.00
D
Reflects the portion of 117,378 shares of the Issuer's common stock held by Novalis LifeSciences Investments I, L.P. (the "Fund") in which the Reporting Person had a pecuniary interest.
This transaction was executed in multiple trades at prices ranging from $32.3489 to $32.5662. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The Reporting Person had sole voting and investment control over all of the shares owned by the Fund and had a pecuniary interest in 27,619 of the shares.
Includes 2,270 restricted stock units.
/s/ Brian Keane, as Attorney-in-Fact
2020-08-11